NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeoGenomics reports robust Q4 earnings, targets profitability in 2023

NeoGenomics delivered strong financial performance in Q4 2022 and full-year 2022, with a focus on sustainable long-term growth. The company aims to achieve adjusted EBITDA positive by Q4 2023 through strategic initiatives, including revenue growth, margin improvement, and operational efficiencies.

NeoGenomics reports robust Q1 results, eyes growth in diagnostics

NeoGenomics' Q1 performance reflects strong revenue growth and operational improvements, driven by strategic priorities and salesforce optimization.
While facing challenges in market share capture and modalities impact, the company's focus on automation and revenue cycle management presents growth opportunities.
Overall, NeoGenomics is well-positioned to achieve its full-year guidance and capitalize on opportunities in advanced diagnostics and revenue optimization.

NeoGenomics excels in Q2, raises guidance on strong growth prospects

NeoGenomics delivered strong financial results, raised revenue guidance, and improved operational efficiencies. With a focus on NGS portfolio expansion, revenue growth, and strategic planning, the company is well-positioned for future success amidst market challenges.

NeoGenomics reports strong Q3 growth, eyes accelerated breast coverage

NeoGenomics demonstrated robust growth and operational improvements in Q3.
The company's focus on high-value areas like breast cancer is a strategic advantage.
Challenges include potential delays in submissions and ongoing labor inflation concerns.
Opportunities lie in accelerated breast coverage, sales force expansion, and payment efficiency enhancements.

NeoGenomics reports strong Q4 earnings and outlines growth strategies

NeoGenomics delivered strong financial performance in Q4 2023, with revenue growth, improved profitability, and a focus on strategic investments for future growth and operational efficiency.
The company's strengths lie in its strategic focus areas, commitment to value creation, and solid financial position, positioning it well for sustainable success and market leadership.
While facing challenges such as market dynamics and operational hurdles, NeoGenomics has opportunities in expanding market share, product innovation, and strategic partnerships to drive growth and profitability.
Overall, NeoGenomics' performance, strengths, challenges, and opportunities indicate a resilient business poised for continued growth, profitability, and market expansion in the evolving healthcare landscape.

NeoGenomics reports robust Q1 growth, eyes M&A and innovation

NeoGenomics delivered strong financial performance in Q1 2024, driven by revenue growth and operational improvements.
The company's strategic priorities, leadership enhancements, and regulatory outlook bode well for future growth and innovation.
While facing challenges in legal defense and market dynamics, NeoGenomics is well-positioned to leverage opportunities in M&A, product launches, and commercial expansion.

NeoGenomics reports robust Q2 growth amidst legal challenges

NeoGenomics delivered strong financial performance in Q2 2024, with revenue growth, positive adjusted EBITDA, and raised revenue guidance for the year.
The company's strategic focus on innovation, operational efficiency, and growth positions it well to capitalize on the evolving healthcare landscape and increasing demand for advanced diagnostics.
While facing legal challenges, NeoGenomics is actively exploring solutions and remains committed to driving value creation and expanding its market presence through product development and strategic initiatives.

NeoGenomics reports record Q3 earnings, eyes growth through innovation

NeoGenomics delivered strong financial performance in Q3 2024, with record revenues and improved adjusted EBITDA, driven by NGS growth.
The company's strategic focus on sustainable growth, innovation, and financial management strengths position it well for future success.
Challenges lie in addressing profitability evolution, successful Neo Helix integration, and balancing short-term impact with long-term value creation.
Opportunities include Neo Helix development, revenue mix diversification, and achieving the revised adjusted EBITDA guidance range.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your NeoGenomics investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securit

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) investors concerning the Company's possible violations of federal securities laws. On March 28, 2022, after the market closed, NeoGenomics announced that its Chief Executive Officer, Mark Mallon, had resigned, less than a year after accepting the position. The Company also stated that revenue for first quarter 2022 would be “belo

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On March 28, 2022, after the market closed, NeoGenomics announced that its Chief Executive Officer, Mark Mallon, had resigned, less than a year after accepting the position

The Law Offices of Frank R. Cruz Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). The investigation concerns whether NeoGenomics has violated the federal securities laws and/or engaged in other unlawful business practices. NeoGenomics specializes in cancer genetics testing and information services and aims to provide comprehensive oncology-focused testing menus in the world for physicians to help them diagn

Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of NeoGenomics, Inc. (NEO) Investors

Cancer-testing company NeoGenomics is down more than 30% today after lowering earnings expectations. How far will NEO stock fall?

Why Is NeoGenomics (NEO) Stock Down Today?

LOS ANGELES--(BUSINESS WIRE)---- $NEO #NEO--The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm

NeoGenomics Inc's (NASDAQ: NEO) CEO Mark Mallon will step down as CEO and member of the Board, effective immediately.  The Board has retained Russell Reynolds to search for the Company's next CEO The Board has appointed current Chair Lynn Tetrault, Esq.

Why NeoGenomics Stock Is Plunging Today

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, announces that it is investigating NeoGenomics Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO) for potential violations of the federal securities laws. On Monday, March 28, 2022, NeoGenomics Inc. Chief Executive Mark Mallon stepped down as the health-testing company revealed that first-quarter financials will miss guidance and rescinded its forecast for the full year, sending shar

SHAREHOLDER ALERT - Labaton Sucharow Investigating NeoGenomics Inc. - NEO

NeoGenomics Inc. Chief Executive Mark Mallon stepped down Monday as the health-testing company revealed that first-quarter financials will miss guidance and rescinded its forecast for the full year, sending shares down more than 20% in after-hours trading.

NeoGenomics stock plunges more than 20% as CEO departs after disappointing quarter

Board Appoints Executive Chair and Interim Office of the CEO Anticipates First Quarter Results Below Guidance and Withdraws 2022 Guidance FT. MYERS, FL / ACCESSWIRE / March 28, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that the Board of Directors (the "Board") and Mark Mallon, Chief Executive Officer, have agreed that Mr.

NeoGenomics Announces CEO Departure and Initiates CEO Search

Study further highlights potential of RaDaR to stratify patients and improve treatment outcomes FT. MYERS, FL / ACCESSWIRE / March 17, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has announced the publication of new data in support of its RaDaR™ liquid biopsy test in patients with early-stage non-small cell lung cancer (NSCLC).

NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer

Inivata and Collaborators Publish Clinical Validation Data for RaDaR ™ Assay in  Non-Small Cell Lung Cancer

Inivata and Collaborators Publish Clinical Validation Data for RaDaR™ Assay in Non-Small Cell Lung Cancer

NeoGenomics (NEO) CEO, Mark Mallon on Q4 2021 Results - Earnings Call Transcript

Recent Highlights: Full year 2021 consolidated revenue increased 9% year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 16% Fourth quarter consolidated revenue was flat year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 7% Inivata Limited, a wholly owned subsidiary of NeoGenomics ("Inivata"), received the CE mark for its RaDaR™ assay in January 2022 for the detection of molecular residual disease and recurrence and submitted to the MolDX program in the United States for the reimbursement of RaDaR™ for clinical testing FT. MYERS, FL / ACCESSWIRE / February 23, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced fourth quarter and full year 2021 results for the period ended December 31, 2021.

NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021

FT. MYERS, FL / ACCESSWIRE / February 14, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has announced that Shashikant Kulkarni, M.S (Medicine)., Ph.D., MBA, FACMG will be joining the NeoGenomics executive team as Executive Vice President for Research & Development and Chief Scientific Officer on March 7th.

NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer

Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR TM in Head and Neck Squamous Cell Carcinoma

Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR™ in Head and Neck Squamous Cell Carcinoma

RaDaR demonstrated 100% specificity in patients with no recurrence and 100% sensitivity in patients with clinical recurrence FT MYERS, FL / ACCESSWIRE / February 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has announced clinical validation data for its RaDaRTM liquid biopsy test in head and neck squamous cell carcinoma (HNSCC). The data from the Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study have been published in the British Journal of Cancer and can be viewed here.

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma

FT. MYERS, FL / ACCESSWIRE / February 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that members of senior management will be participating virtually in multiple upcoming institutional investor conferences. Management will participate in investor meetings and a fireside chat at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on Thursday, February 17, 2022.

NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences

FT MYERS, FL / ACCESSWIRE / February 2, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its fourth quarter 2021, financial results on Wednesday, February 23, 2022. The Company has scheduled a webcast and conference call to discuss their fourth quarter and full year 2021 results on Wednesday, February 23, 2022 at 8:30 AM EDT.

NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022

The partnership makes it possible for patients with specific biomarkers to get early support FT. MYERS, FL / ACCESSWIRE / January 24, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced a strategic partnership with the Biomarker Collaborative to help cancer patients who test positive for specific biomarkers connect to support groups that include patients with similar findings.

NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results

Hillenbrand

See two of the featured stocks from this month's model portfolios.

The Good And Bad: Hillenbrand & NeoGenomics

FT. MYERS, FL / ACCESSWIRE / January 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has received the CE mark for its RaDaR™ assay for the detection of molecular residual disease (MRD) and recurrence, having met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC). In addition, Inivata has submitted to the MolDX program in the US for the reimbursement of RaDaR for clinical testing.

NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program

Inivata Announces RaDaR ™ Assay Receives CE Mark and is Submitted for US Reimbursement v ia the MolDX Program

Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program

NeoGenomics has established itself with a strong market position in the expanding field of cancer diagnostics. NeoGenomics is all about growth planning to grow at twice the market rate.

News for NeoGenomics Stock (NEO)